GlassScriptPhysician profile
Karyn E Mills
NPI 1538305438
$697.21
in general payments reported to CMS, 2019-2025
15 companies · $684 in 2025
The $684 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $13.68 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $697.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $137.97 | 2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $107.04 | 2024-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $85.54 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $54.06 | 2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $47.16 | 2025 | |
| Axsome Therapeutics, INC. | $44.56 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $44.01 | 2025 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $35.17 | 2025 | Trintellix |
| Sumitomo Pharma America, INC. | $27.20 | 2025 | Gemtesa |
| Lundbeck LLC | $23.94 | 2025 | Rexulti |
| Pfizer INC. | $22.47 | 2025 | |
| Corcept Therapeutics | $20.80 | 2025 | Korlym |
| Ardelyx, INC. | $16.66 | 2025 | Ibsrela |
| Esperion Therapeutics, INC. | $15.64 | 2025 | Nexletol |
| Shield Therapeutics INC | $14.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karyn Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.